TXG Stock Recent News

10x Genomics (TXG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.

PLEASANTON, Calif. , May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025.

Results in line with expectations and tracking well to full-year guidance (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 7, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three months ended March 31, 2025. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.

Milestone marks the Company's official transition to become both a gold and copper producer (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 1, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to announce it has achieved commercial production at the Media Luna mine, concluding the development phase of the Media Luna Project. Amongst other criteria, commercial production is declared when construction is substantially complete, mine and mill throughput have averaged over 40% and 60% of design rates for 30 days, respectively, product is saleable, and metallurgical recoveries have averaged at least 60% of the design recovery levels.

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLEASANTON, Calif. , April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m.

Processing plant tie-ins concluded and first copper concentrate achieved; quarterly production in line with plan (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q1 2025 gold equivalent ("AuEq") payable production of 59,630 ounces ("oz") and AuEq sold of 60,568 oz. The Company is on track to achieve annual payable production guidance of 400,000 to 450,000 oz AuEq1.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #neuroscience--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of litigation between Vizgen, Harvard University and 10X Genomics in the United States District Court for the District of Delaware. Dear Customers, Researchers and Friends of Vizgen: On February 5th, we secured an important settlement putting an end to litigation, including.

Processing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces completion of the four-week tie-in period for the Media Luna Project ("Media Luna") and first production of precious metal-rich copper concentrate. Jody Kuzenko, President and CEO of Torex, stated: "Following almost three years to the day of the release of our feasibility study for the Media Luna Project, we have completed the tie-in period at our processing plant and achieved first production of copper concentrate.

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify holding the stock at current price levels.